Ruxolitinib has been identified as a potential effective treatment for parkinsonism arising from receipt of ciltacabtagene autoleucel in patients with multiple myeloma. A recently published case report detailed two patients with multiple myeloma who developed parkinsonism after receiving the CAR T-cell therapy, which was effectively controlled with ruxolitinib.
Use of Ruxolitinib to Resolve Ciltacabtagene Autoleucel–Induced Parkinsonism in Patients With Multiple Myeloma
Ruxolitinib may prove to be an effective treatment of parkinsonism arising from ciltacabtagene autoleucel treatment for patients with multiple myeloma, according to the results of two case studies published in the Journal of Hematology.
The ASCO Post
05/02/2025 9:34 AM
